Actualités

LABATEC PHARMA ANNOUNCES AN EXCLUSIVE LICENSING AGREEMENT SIGNED WITH AFT PHARMACEUTICALS, TO COMMERCIALISE MAXIGESIC IV®, IN SWITZERLAND   Geneva, March 27, 2023 – Labatec Pharma SA (Labatec) signed a new licensing agreement with AFT Pharmaceuticals (NZX.AFT, ASX.AFP), for the exclusive rights to commercialise Maxigesic IV® in Switzerland, a treatment for mild to moderate pain for use […]

Nous savons qu’il existe différents outils pour éliminer le virus et pour prévenir les cancers que le papillomavirus peut causer. Papilocare® est le premier traitement indiqué dans la prévention et le traitement des lésions cervicales de bas grade, provoquées par le papillomavirus : plus d’informations sur www.papilocare.ch ou écrivez-nous à papilocare@labatec.com. Il est temps de […]

LABATEC PHARMA ANNOUNCES EXCLUSIVE LICENSING AGREEMENT SIGNED WITH RADIUS HEALTH INC, TO COMMERCIALISE TYMLOS IN SWITZERLAND AND THE MIDDLE EAST NORTH AFRICA REGION   Geneva, June 9, 2022 – Labatec Pharma SA (Labatec) signed a new licensing agreement with Radius Health, Inc. (Radius) (NASDAQ: RDUS), for the rights to commercialise TYMLOS® (abaloparatide), a subcutaneous injection […]